Should I buy or sell Eyenovia stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EYEN shares. View EYEN analyst ratings or view top-rated stocks .

What is Eyenovia's stock price target for 2024?

3 brokers have issued 1-year price objectives for Eyenovia's stock. Their EYEN share price targets range from $8.00 to $12.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 624.6% from the stock's current price. View analysts price targets for EYEN or view top-rated stocks among Wall Street analysts .

How have EYEN shares performed in 2023?

Eyenovia's stock was trading at $1.63 at the start of the year. Since then, EYEN shares have decreased by 15.3% and is now trading at $1.38. View the best growth stocks for 2023 here .

Are investors shorting Eyenovia?

Eyenovia saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,960,000 shares, an increase of 12.0% from the October 31st total of 1,750,000 shares. Based on an average daily trading volume, of 266,200 shares, the short-interest ratio is presently 7.4 days. View Eyenovia's Short Interest .

When is Eyenovia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our EYEN earnings forecast .

How were Eyenovia's earnings last quarter?

Eyenovia, Inc. (NASDAQ:EYEN) issued its quarterly earnings results on Monday, November, 13th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.01.

What other stocks do shareholders of Eyenovia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyenovia investors own include Sorrento Therapeutics (SRNE) , OPKO Health (OPK) , Vaxart (VXRT) , Axsome Therapeutics (AXSM) , Aldeyra Therapeutics (ALDX) , Leap Therapeutics (LPTX) , Trevena (TRVN) , Albireo Pharma (ALBO) , BioXcel Therapeutics (BTAI) and Corvus Pharmaceuticals (CRVS) .

When did Eyenovia IPO?

(EYEN) raised $30 million in an IPO on Thursday, January 25th 2018. The company issued 2,700,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO.

Who are Eyenovia's major shareholders?

Eyenovia's stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (8.08%), Financial Management Network Inc. (0.21%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bren Kern, Charles E Iv Mather , Ellen R Strahlman, John P Gandolfo, Kenneth B Lee Jr , Michael M Rowe, Michael M Rowe , Stuart M Grant and Tsontcho Ianchulev . View institutional ownership trends .

How do I buy shares of Eyenovia?

Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Eyenovia Stock Price, News & Analysis (NASDAQ:EYEN)

$1.41

+0.05 (+3.86%)

(As of 12:15 PM ET)

Compare

Today's Range: $1.35
▼
$1.42
50-Day Range: $1.08
▼
$1.72
52-Week Range: $1.05
▼
$5.85

Volume: 183,922 shs
Average Volume: 331,617 shs
Market Capitalization: $62.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Eyenovia MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 624.6% Upside
$10.00 Price Target
Short Interest: Bearish
4.44% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.50
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$19,062 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.68) to ($0.81) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

697th out of 958 stocks

Pharmaceutical Preparations Industry

293rd out of 393 stocks

3.5

Analyst's Opinion

Consensus Rating
Eyenovia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, Eyenovia has a forecasted upside of 624.6% from its current price of $1.38.
Amount of Analyst Coverage
Eyenovia has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.44% of the outstanding shares of Eyenovia have been sold short.
Short Interest Ratio / Days to Cover
Eyenovia has a short interest ratio ("days to cover") of 7.4.
Change versus previous month
Short interest in Eyenovia has recently increased by 12.00%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Eyenovia does not currently pay a dividend.
Dividend Growth
Eyenovia does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EYEN.

2.5

News and Social Media Coverage

News Sentiment
Eyenovia has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Eyenovia this week, compared to 1 article on an average week.
Search Interest
2 people have searched for EYEN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eyenovia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,062.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 7.80% of the stock of Eyenovia is held by insiders.
Percentage Held by Institutions
Only 16.66% of the stock of Eyenovia is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Eyenovia are expected to decrease in the coming year, from ($0.68) to ($0.81) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eyenovia is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eyenovia is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Eyenovia has a P/B Ratio of 2.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Eyenovia Stock (NASDAQ:EYEN)

Eyenovia, Inc., a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi in rest of Asia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

EYEN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EYEN Stock News Headlines

December 6, 2023 | msn.com

Insiders Buying Eyenovia And 3 Other Stocks Under $2

November 23, 2023 | finanznachrichten.de

Eyenovia, Inc.: Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update

December 7, 2023 | Edge On The Street (Ad)

Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?

A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.

November 16, 2023 | uk.finance.yahoo.com

Eyenovia, Inc. (EYEN) stock price, news, quote & history – Yahoo Finance

November 14, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Arcellx Inc (ACLX), Clearside Biomedical (CLSD)

November 14, 2023 | finance.yahoo.com

Eyenovia, Inc. (NASDAQ:EYEN) Q3 2023 Earnings Call Transcript

November 13, 2023 | msn.com

Eyenovia GAAP EPS of -$0.18 in-line, revenue of $1.19M beats by $1.03M

November 13, 2023 | finance.yahoo.com

Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update

December 7, 2023 | Financial Alphas (Ad)

Recent Reports Are A Wake-Up Call For Investors

As the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.

November 9, 2023 | finance.yahoo.com

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

November 6, 2023 | finance.yahoo.com

Eyenovia to Report Third Quarter 2023 Results on Monday, November 13

November 2, 2023 | msn.com

William Blair Initiates Coverage of Eyenovia (EYEN) with Outperform Recommendation

November 2, 2023 | finance.yahoo.com

Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production

November 1, 2023 | benzinga.com

Eyenovia Stock (NASDAQ:EYEN), Analyst Ratings, Price Targets, Predictions

November 1, 2023 | markets.businessinsider.com

Eyenovia's Stock Is Soaring Today - Here's Why

October 30, 2023 | insidermonkey.com

Billionaire Marc Lasry’s Top 10 Stock Picks

October 30, 2023 | finance.yahoo.com

Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program

October 18, 2023 | msn.com

Brookline Capital Initiates Coverage of Eyenovia (EYEN) with Buy Recommendation

October 9, 2023 | finance.yahoo.com

Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®

September 21, 2023 | finance.yahoo.com

Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference

September 7, 2023 | finance.yahoo.com

Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference

August 28, 2023 | msn.com

Eyenovia: It Is Now Time To See Positive Results In Their Marketing Efforts

August 24, 2023 | finance.yahoo.com

Eyenovia Announces $12 Million Registered Direct Offering

August 18, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Eyenovia (EYEN)

August 16, 2023 | msn.com

Eyenovia acquires US licencing rights for Formosa’s topical eye steroid

August 16, 2023 | markets.businessinsider.com

Formosa Pharma: Eyenovia Obtains U.S. Rights For Commercialization Of APP13007

August 16, 2023 | finance.yahoo.com

Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals

See More Headlines

Receive EYEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eyenovia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 12/07/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:EYEN
CUSIP: N/A
CIK: 1682639
Web: www.eyenoviabio.com
Phone: (917) 289-1117
Fax: N/A
Employees: 41
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $12.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +635.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.66)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-28,010,000.00
Net Margins: N/A
Pretax Margin: -2,541,699.75%
Return on Equity: -171.30%
Return on Assets: -81.62%

Debt

Debt-to-Equity Ratio: 0.70
Current Ratio: 4.05
Quick Ratio: 4.04

Sales & Book Value

Annual Sales: $14 million
Price / Sales: 4.29
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.48 per share
Price / Book: 2.83

Miscellaneous

Outstanding Shares: 44,120,000
Free Float: 40,680,000
Market Cap: $60.00 million
Optionable: Not Optionable
Beta: 1.73

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Tsontcho Ianchulev M.D. (Age 49)
M.P.H., MPH, Co-Founder & Executive Chairman
Comp: $920.87k
Mr. Michael M. Rowe (Age 61)
CEO & Director
Comp: $750.01k
Mr. John P. Gandolfo CPA (Age 62)
CFO & Secretary
Comp: $598.39k
Mr. Bren Kern (Age 42)
COO & Corporate VP
Alexander Lobo
Investor Contact

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EYEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Eyenovia stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EYEN shares.
View EYEN analyst ratings or view top-rated stocks.
What is Eyenovia's stock price target for 2024?: 3 brokers have issued 1-year price objectives for Eyenovia's stock. Their EYEN share price targets range from $8.00 to $12.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 624.6% from the stock's current price.
View analysts price targets for EYEN or view top-rated stocks among Wall Street analysts.
How have EYEN shares performed in 2023?: Eyenovia's stock was trading at $1.63 at the start of the year. Since then, EYEN shares have decreased by 15.3% and is now trading at $1.38.
View the best growth stocks for 2023 here.
Are investors shorting Eyenovia?: Eyenovia saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,960,000 shares, an increase of 12.0% from the October 31st total of 1,750,000 shares. Based on an average daily trading volume, of 266,200 shares, the short-interest ratio is presently 7.4 days.
View Eyenovia's Short Interest.
When is Eyenovia's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our EYEN earnings forecast.
How were Eyenovia's earnings last quarter?: Eyenovia, Inc. (NASDAQ:EYEN) issued its quarterly earnings results on Monday, November, 13th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.01.

What other stocks do shareholders of Eyenovia own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Eyenovia investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Vaxart (VXRT), Axsome Therapeutics (AXSM), Aldeyra Therapeutics (ALDX), Leap Therapeutics (LPTX), Trevena (TRVN), Albireo Pharma (ALBO), BioXcel Therapeutics (BTAI) and Corvus Pharmaceuticals (CRVS).
When did Eyenovia IPO?: (EYEN) raised $30 million in an IPO on Thursday, January 25th 2018. The company issued 2,700,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO.
Who are Eyenovia's major shareholders?: Eyenovia's stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (8.08%), Financial Management Network Inc. (0.21%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bren Kern, Charles E Iv Mather, Ellen R Strahlman, John P Gandolfo, Kenneth B Lee Jr, Michael M Rowe, Michael M Rowe, Stuart M Grant and Tsontcho Ianchulev.
View institutional ownership trends.
How do I buy shares of Eyenovia?: Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:EYEN) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial